title: Clinical predictive factors of poor outcome in patients with stage pT0 disease at radical cystectomy.
abstract: OBJECTIVE
  We evaluated new pre-cystectomy predictive factors for outcomes in patients with no evidence of residual tumor at cystectomy (pT0).
  
  
  METHODS
  A total of 1,114 patients underwent radical cystectomy at our institution between August 1978 and June 2002, of whom 141 (12.66%) had stage pT0. We analyzed overall and disease specific survival in relation to pre-cystectomy predictive factors, such as clinical stage, grade, size, previous nonmuscle invasive disease, number of previous recurrences, associated carcinoma in situ and lymphovascular invasion in the transurethral resection. Other factors analyzed were lymph node (N+) at cystectomy and induction chemotherapy.
  
  
  RESULTS
  Clinical stage was cTa in 10 patients, cT1 in 34, cT2 in 55, cT3 in 30 and cTis in 12. At a median followup of 42.5 months overall survival was 62.53% and disease specific survival was 79.14%. Metastatic disease developed in 17 cases (12.1%). Univariate analysis revealed worse disease specific survival in patients in whom muscle invasive tumor developed after nonmuscle invasive disease (p<0.05), and in those who presented with 5 or more previous recurrences (p<0.05), lymphovascular invasion in the transurethral resection (p<0.05) and N+ at cystectomy (p<0.05). Multivariate analysis confirmed a statistically significant association between disease specific survival and 5 or more previous recurrences (HR 1.5, 95% CI 1.07-2.10, p=0.018), muscle invasive tumor after nonmuscle invasive disease (HR 4.4, 95% CI 1.20-16.5, p=0.026) and lymphovascular invasion in the transurethral resection (HR 1.7, 95% CI 1.12-2.30, p=0.04).
  
  
  CONCLUSIONS
  Although clinical outcomes in patients with stage pT0 disease are often excellent, metastatic disease develops in a percentage of them. Muscle invasive tumor after primary nonmuscle invasive disease, 5 or more previous recurrences and lymphovascular invasion in the transurethral resection predict poor survival.
authors.affiliation: Department of Urology and Section of Pathology (FA), Universitat Autonoma de Barcelona, Fundació Puigvert, Barcelona, Spain. orodriguez@fundacio-puigvert.es
authors.forename: Oscar
authors.initials: O
authors.lastname: Rodriguez Faba
authors.forename: Juan
authors.initials: J
authors.lastname: Palou
authors.forename: Antonio
authors.initials: A
authors.lastname: Rosales
authors.forename: Alberto
authors.initials: A
authors.lastname: Breda
authors.forename: Ferran
authors.initials: F
authors.lastname: Algaba
authors.forename: Guillermo
authors.initials: G
authors.lastname: Urdaneta
authors.forename: Humberto
authors.initials: H
authors.lastname: Villavicencio
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015653:Cystectomy / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000601:surgery*